ORM-10921
ORM-10921 is an α-2c adrenergic receptor antagonist potentially for the treatment of schizophrenia. In the pharmacodynamic microdialysis study, ORM-10921 was found to increase extracellular dopamine levels in prefrontal cortex in the baseline conditions. In the behavioural tests, ORM-10921 displayed potent antidepressant and antipsychotic-like effects in the forced swimming test and prepulse-inhibition models analogously with the previously reported results with structurally different α2C-selective AR antagonist JP-1302.
| Supplier | Ace Therapeutics |
|---|---|
| Product # | SMD1627 |
| CAS # | 610782-82-6 (free base) |
| Pricing | Customizable size, Inquiry |
| Synonym | ORM-10921; ORM 10921; ORM10921 |
| Product Category | Lab-use Small Molecule Drugs |
| Chemical Formula | C18H23NO2 |
| Exact Mass | 285.1729 |
| Molecular Weight | 285.387 |
| Elemental Analysis | C, 75.76; H, 8.12; N, 4.91; O, 11.21 |
| IUPAC/Chemical Name | (1S,12bS)-1-(methoxymethyl)-1-methyl-1,3,4,6,7,12b-hexahydro-2H-benzofuro[2,3-a]quinolizine |
| InChi Key | OCUKPFWNSAAHRP-QZTJIDSGSA-N |
| InChi Code | InChI=1S/C18H23NO2/c1-18(12-20-2)9-5-10-19-11-8-14-13-6-3-4-7-15(13)21-16(14)17(18)19/h3-4,6-7,17H,5,8-12H2,1-2H3/t17-,18-/m1/s1 |
| SMILES Code | C[C@]1(COC)CCCN2CCC3=C(OC4=CC=CC=C43)[C@]12[H] |
| Appearance | Solid powder |
| Purity | >98% (or refer to the Certificate of Analysis) |
| Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
| Storage Condition | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| Solubility | Soluble in DMSO |
| Shelf Life | >2 years if stored properly |
| Drug Formulation | This drug may be formulated in DMSO |
| Stock Solution Storage | 0 - 4℃ for short term (days to weeks), or -20℃ for long term (months). |
| HS Tariff Code | 2934.99.9001 |
| Class-2 | Depression |